<code id='792D8FFE60'></code><style id='792D8FFE60'></style>
    • <acronym id='792D8FFE60'></acronym>
      <center id='792D8FFE60'><center id='792D8FFE60'><tfoot id='792D8FFE60'></tfoot></center><abbr id='792D8FFE60'><dir id='792D8FFE60'><tfoot id='792D8FFE60'></tfoot><noframes id='792D8FFE60'>

    • <optgroup id='792D8FFE60'><strike id='792D8FFE60'><sup id='792D8FFE60'></sup></strike><code id='792D8FFE60'></code></optgroup>
        1. <b id='792D8FFE60'><label id='792D8FFE60'><select id='792D8FFE60'><dt id='792D8FFE60'><span id='792D8FFE60'></span></dt></select></label></b><u id='792D8FFE60'></u>
          <i id='792D8FFE60'><strike id='792D8FFE60'><tt id='792D8FFE60'><pre id='792D8FFE60'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:Wikipedia    Page View:97723
          the shape of a medical note connected by dots and lines — health tech coverage from STAT
          Adobe

          In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers.

          But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI? Can it be used at all to make decisions about the coverage of older patients? If so, how?

          advertisement

          This week, the federal agency that oversees Medicare sought to boil it all down into a simple directive: Put the circumstances of the individual patient first, and your algorithm second.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Merck, Johnson & Johnson CEOs will testify on high drug prices
          Merck, Johnson & Johnson CEOs will testify on high drug prices

          Johnson&JohnsonCEOJoaquinDuatoMICHAELBUHOLZER/AFPviaGettyImagesWASHINGTON—MerckCEORobertDavisand

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Inflation cooled significantly in June, bringing price hikes close to normal levels

          1:39ProducepricesaredisplayedatagrocerystoreinBrooklyn,Feb.14,2023.XinhuaNewsAgencyviaGettyImagesCon